Evicenter
P&T meetings

Molgramostim Inhalation Solution

Autoimmune pulmonary alveolar proteinosis

Manufacturer
Savara
Regulatory submission
BLA resubmitted December 2025
Launch
Not announced
Last updated
89 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Autoimmune pulmonary alveolar proteinosis

3 evidence topics · 3 sources

United States claims analysis: all PAP subtypes

“2018” (opens the source at this quote in a new tab)

“The annual prevalence of PAP in the general population was 6.87 ±0.33 per million” (opens the source at this quote in a new tab)

“likely a minimum estimate of true prevalence” (opens the source at this quote in a new tab)

Updated United States claims-based autoimmune PAP population estimate

“September 2, 2025” (opens the source at this quote in a new tab)

“Autoimmune PAP prevalence rates were applied to the confirmed PAP population” (opens the source at this quote in a new tab)

“resulting in ~5,500 autoimmune PAP patients in the U.S.” (opens the source at this quote in a new tab)

Japanese registry: smoking and dust exposure

“a Japanese national registry” (opens the source at this quote in a new tab)

“A history of smoking occurred in 56%, and dust exposure occurred in 23%; instances of familial onset did not occur.” (opens the source at this quote in a new tab)